Enbridge Inc T.ENB

Alternate Symbol(s): T.ENB.PR.B | T.ENB.PR.Y | T.ENB.PR.D | ENBFF | ENB | T.ENB.PR.F | ENBGF | T.ENB.PF.A | T.ENB.PR.G | ENBHF | ENNPF | T.ENB.PF.C | T.ENB.PR.H | T.ENB.PF.E | T.ENB.PR.I | ENBMF | EBRGF | T.ENB.PF.G | T.ENB.PR.J | ENBNF | T.ENB.PF.K | T.ENB.PR.N | ENBOF | EBRZF | T.ENB.PF.U | EBBGF | T.ENB.PR.P | EBGEF | T.ENB.PF.V | EBBNF | T.ENB.PR.T | ENBRF | T.ENB.PR.A | T.ENB.PR.V

Energy Oil & Gas Midstream

Enbridge Inc. is an energy transportation and distribution company. The Company operates through five business segments: Liquids Pipelines, Gas Transmission and Midstream, Gas Distribution and Storage, Renewable Power Generation, and Energy Services. Liquids Pipelines consists of pipelines and terminals in Canada and the United States that transport and export various grades of crude oil and other liquid hydrocarbons. Gas Transmission and Midstream consists of its investments in natural gas pipelines and gathering and processing facilities in Canada and the United States. Gas Distribution and Storage consists of its natural gas utility operations. Renewable Power Generation consists of investments in wind and solar assets, geothermal, waste heat recovery, and transmission assets. Energy Services provides physical commodity marketing, logistics services, and energy marketing services. The Company owns Aitken Creek Gas Storage facility and Aitken Creek North Gas Storage facility.

TSX:ENB - Post by User

Enbridge Inc > Some Thoughts about This or That

<< Previous

Bullboard Posts

Next >>

Comment by Abouttime1on Nov 10, 2020 5:06pm

96 Views

Post# 31874544

RE:RE:RE:Some Thoughts about This or That

Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study

Vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis
Analysis evaluated 94 confirmed cases of COVID-19 in trial participants
Study enrolled 43,538 participants, with 42% having diverse backgrounds, and no serious safety concerns have been observed; Safety and additional efficacy data continue to be collected
Submission for Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) planned for soon after the required safety milestone is achieved, which is currently expected to occur in the third week of November
Clinical trial to continue through to final analysis at 164 confirmed cases in order to collect further data and characterize the vaccine candidate’s performance against other study endpoints